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A ntiglomerular basement membrane (GBM) diseaseis an autoimmune disease that classically presents
as a rapidly progressive crescentic glomerulonephritis,
with or without pulmonary hemorrhage, and typically
does not relapse.1 The anti-GBM autoantibodies, typi-
cally polyclonal IgG1 and IgG4,2,3 bind to the non-
collagenous 1 domain of the alpha-3 chain of type IV
collagen that is present on alveolar and glomerular
basement membranes.2–4 Kidney biopsies in patients
with anti-GBM disease reveal a crescentic and necro-
tizing glomerulonephritis on light microscopy with
diffuse linear staining of the glomerular basement
membrane for IgG on immunoﬂuorescence (IF) micro-
scopy.1,4 Anti-GBM antibodies are detectable in the
serum of w90% of patients using conventional
enzyme-linked immunosorbent assays.4 Atypical anti-
GBM disease is a rare entity deﬁned by uncharacteristic
histologic features on light microscopy and/or linear
GBM staining for an antibody other than the typical
polyclonal IgG on IF.2 Here we describe a case of re-
lapsing, atypical IgG1-k anti-GBM glomerulonephritis.
CASE PRESENTATION
A 39-year-old African-American woman with a history
of morbid obesity and hypertension presented to a
hospital 5 years ago with cough, hemoptysis, diarrhea,
and emesis. Physical examination was notable for a
temperature of 101 F (38.3 C), blood pressure of
142/59 mm Hg, and heart rate of 103 beats per minute;
she had no edema and her lungs were clear to auscul-
tation bilaterally. A chest X-ray did not show any
inﬁltrates. She underwent an esophagogastroduodeno-
scopy and a colonoscopy to further evaluate
her gastrointestinal symptoms. Her esophagogas-
troduodenoscopy test result was unremarkable and her
colonic biopsy showed mild-acute chronic ileitis withpoorly formed granulomatous inﬂammation presumed
to be autoimmune or infectious in nature. She was also
found to have acute kidney injury with a serum
creatinine (SCr) level of 3.6 mg/dl (normal range 0.57–1
mg/dl) with an estimated glomerular ﬁltration rate by
Modiﬁcation of Diet in Renal Disease equation of 18 ml/
min per 1.73 m2. Her Scr level peaked at 8.6 mg/dl. Her
urinalysis was signiﬁcant for microscopic hematuria
and albuminuria, and a spot urine protein to creatinine
ratio was 3.3 g/g (normal range 0–200 mg/g). Anti-GBM
(by enzyme-linked immunosorbent assay) and ANCA
serologies (by immunoﬂuorescence) were negative. Her
C3 level was mildly decreased at 76 mg/dl (normal
range 88–201 mg/dl) and her C4 level was mildly
elevated at 46 mg/dl (normal range 14–44 mg/dl).
Serum protein electrophoresis showed no monoclonal
spike, and her serum free light chain levels were
normal (k ¼ 8.6 mg/dl [range 3.3-19.4 mg/dl] and l ¼
5.7–26.3 mg/dl).
A kidney biopsy was performed (Figure 1). Light
microscopy showed 9 glomeruli with segmental endo-
capillary hypercellularity with intracapillary leuko-
cytes and segmental glomerular basement membrane
duplication, 3 glomeruli with cellular crescents and
segmental ﬁbrinoid necrosis, patchy interstitial edema,
and moderate to severe interstitial inﬂammation. There
was no signiﬁcant interstitial ﬁbrosis and tubular at-
rophy and the vessels were normal. IF microscopy
revealed bright diffuse linear staining of the glomerular
basement membrane with IgG1 (2þ) and kappa (2þ)
light chain. There was focal staining of tubular base-
ment membranes and no staining of Bowman capsule
basement membrane. There was staining of the
glomerular capillary wall and mesangium with C3 (2þ).
There was no detectable staining for IgG2, IgG3, IgG4,
IgM, IgA, C1, or lambda light chain. The IF was
negative for albumin. Electron microscopy was signif-
icant for 20% foot process effacement and no electronKidney International Reports (2017) 2, 80–83
Figure 1. Histologic ﬁndings in the initial biopsy specimen. (a) Light microscopy shows a glomerulus with cellular crescent (black arrow) (Jones
silver methenamine stain, original magniﬁcation x 400). (b) The same glomerulus shows segmental ﬁbrinoid necrosis (black arrow) (trichome
stain, original magniﬁcation x 400). Immunoﬂuorescence stains (all magniﬁcations x 400) show staining of glomerular basement membranes for
(c) IgG1, (d) kappa light chain, and (e) negative light chain lambda staining.
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duction therapy with pulse methylprednisolone (1 g
i.v. daily for 3 days) followed by oral prednisone 60
mg/d, plasma exchange therapy for 4 sessions, and oral
cyclophosphamide (150 mg/d) for 6 months. Her
prednisone therapy was tapered to off to the point at
which at 6 months she was started on maintenance
therapy with azathioprine that was discontinued after 1
year. At that time, her SCr level was 1.2 mg/dl (normal
range 0.57–1 mg/dl), her urine protein to creatinine
ratio was 55 mg/g (normal range 0–200 mg/g), and her
microscopic hematuria had resolved. She continued to
receive amlodipine and valsartan for hypertension.
Four years after her initial presentation, she was
admitted to a hospital for shortness of breath, pro-
ductive cough, sinus congestion, emesis, and gross
hematuria. On physical exam, she was afebrile, her
blood pressure was 134/86 mm Hg, her pulse oximetry
was 92% on room air, and her heart rate was 83 beats
per minute. The remainder of the examination was
unremarkable. Her SCr level on presentation was 2.9
mg/dl (normal range 0.57–1 mg/dl), and her urinalysis
was signiﬁcant for proteinuria and hematuria;Kidney International Reports (2017) 2, 80–83microscopy was not performed. Her serologic workup
was again negative for anti-GBM (by enzyme-linked
immunosorbent assay) and ANCA (by immunoﬂuores-
cence) antibodies (p-ANCA titer < 1:20, c-ANCA
titer < 1:20, antimyeloperoxidase antibody <9 U/ml,
and antiproteinase-3 <3.5 U/ml). Serum protein elec-
trophoresis, serum immunoﬁxation, and serum kappa/
lambda free light chain showed no evidence of a par-
aprotein. Her serum Ig studies were IgG 1340 mg/dl
(range 650–2000 mg/dl), IgA 141 mg/dl (range 50–500
mg/dl), and IgM 99 mg/dl (range 40–270 mg/dl). A
computed tomography scan of her chest without i.v.
contrast was unremarkable.
Her renal ultrasound showedkidneyswithnormal size
and echotexture. She underwent a second kidney biopsy
that again demonstrated focal necrotizing and crescentic
glomerulonephritis on light microscopy with 20%
interstitial ﬁbrosis and tubular atrophy and mild arte-
riosclerosis. Immunoﬂuorescence was signiﬁcant for
linear IgG1-k GBM staining. A cystoscopy test was
negative. Due to concern that the IgG1-k represented a
monoclonal gammopathy of renal signiﬁcance, she was
referred to hematology for evaluation of a clonal B cell or81
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showed no overt immunophenotypic evidence of a clonal
lymphoproliferative disorder. A bone marrow biopsy
and aspirate smear were also performed. Microscopic
examination of the aspirate smear demonstrated normo-
cellular marrow with trilineage hematopoiesis. Flow
cytometry on the bone marrow aspirate demonstrated
unremarkable T cells, precursor B cells, natural killer
cells, and polytypic B cells. There was no morphologic or
immunophenotypic evidence of a B cell lymphoproli-
ferative disorder, nor an expansion of plasma cells. She
was treated with pulse i.v. steroids followed by oral
prednisone at 60 mg daily and rituximab 1000 mg i.v.
biweekly for 2 doses. Her prednisone therapy was
tapered off across 3.5 months due to signiﬁcant weight
gain, and mycophenolate mofetil was started at 500 mg
twice daily. During the next 4 months, her SCr level
decreased to 1.6 mg/dl (normal range 0.57–1 mg/dl), with
a urine protein to creatinine ratio of 162 mg/g (normal
range 0–200 mg/g). She received a second rituximab
course (1 dose of 1000 mg i.v.) 6 months after her initial
dose. Six months after this dose, while taking myco-
phenolate mofetil 500 mg twice daily, her Scr level is
stable at 1.6mg/dlwith an estimated glomerularﬁltration
rate by Modiﬁcation of Diet in Renal Disease equation of
46 ml/min per 1.73 m2. Her urine protein to creatinine
ratio is 0.2 g/g and her urinalysis continues to show
microscopic hematuria. She has not had recurrence of
pulmonary or gastrointestinal symptoms.
DISCUSSION
Cases of atypical anti-GBM disease are rare and are
deﬁned by unique features on kidney biopsy
compared with typical anti-GBM disease.4 Here we
report a case of relapsing IgG1-k anti-GBM disease
that presented as acute kidney injury and extrarenal
symptoms. No circulating antibodies were detected,
and her SCr level and extrarenal symptoms improved
with immunosuppression. Our case is unique in the
presence of both a relapsing course and extrarenal
(i.e., gastrointestinal and pulmonary) symptoms with
disease activity.
To our knowledge, this is only the third reported
case of IgG1-k anti-GBM disease.2,5 Coley et al.5
described the ﬁrst case of IgG1-k anti-GBM nephritis
in a 53-year-old man who presented with renal insuf-
ﬁciency, hematuria, and proteinuria. A kidney biopsy
showed endocapillary proliferative glomerulonephritis
with no crescents, and linear staining for IgG1-k on IF.
No circulating autoantibodies were detectable. The
patient’s renal function improved with immunosup-
pression (prednisone and cyclophosphamide, then
mycophenolic acid) but relapsed 9 years later with82concomitant symptoms of an upper respiratory infec-
tion, and a repeat kidney biopsy showed the same
ﬁndings in addition to glomerulosclerosis and tubu-
lointerstitial scarring. He again responded to immuno-
suppression (rituximab).
A second patient with IgG1-k anti-GBM disease is
described in a retrospective case series by Nasr et al.2
composed of 20 patients with atypical anti-GBM dis-
ease (deﬁnedby linear IgGBMstaining on IF butwithout
the classic crescentic phenotype). Restricted light chain
staining on IF was observed in 50%of cases. The speciﬁc
details for patients with IgG1-k are not presented, but as
a whole, these patients had a more chronic disease
course, better 1-year survival, no detectable circulating
antibodies, and no pulmonary involvement compared
with those with typical anti-GBM disease.
Because classic anti-GBM tends to have a mono-
phasic course, immunosuppression is usually tapered
off over a period of months after clinical and serologic
remission.6 However, the possible relapsing nature of
IgG1-k anti-GBM disease, as noted in our case and that
of Coley et al.,5 raises the question of how to chroni-
cally manage this disease. We treated our patient
initially using standard therapies for classic anti-GBM
disease. After relapsing, she was treated with ritux-
imab to minimize her cumulative cyclophosphamide
exposure, and additional rituximab and mycophenolate
mofetil were added as steroid-sparing agents for
maintenance immunosuppression. Of note, no relapses
were described in the series by Nasr et al.,2 but rare
cases of relapsing atypical anti-GBM disease, but
without IgG1-k staining, have also been described.4
The pathogenesis of atypical anti-GBM disease and
why these antibodies are not detected on routine
testing is not understood. It is possible that the path-
ogenic antibodies produced by our patient are directed
against an antigen other than the alpha-3 chain of type
IV collagen, or that there is lower or transient antibody
production making it undetectable by standard
tests.1,2,5,7 The light-chain restriction observed on IF
leads to the hypothesis that monotypic anti-GBM dis-
ease is a paraprotein process resulting from a lympho-
proliferative disorder. However, as in our patient, no
associated B or plasma cell clone has been identiﬁed in
the atypical anti-GBM literature. It is possible that this
entity is a monoclonal gammopathy of renal signiﬁ-
cance, because the detection a clonal cell population
has been variable with these disorders as well.
CONCLUSION
We have described a case of IgG1-k anti-GBM disease
notable for its relapsing course and the presence of
extrarenal symptoms. Further work is needed toKidney International Reports (2017) 2, 80–83
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and appropriate treatment strategies to address relapses.
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